AKBA
NASDAQAkebia Therapeutics Inc.
Price$0.94-0.25 (-20.99%)
2026-03-052026-06-08
News · 26 weeks49-78%
2025-12-142026-06-07
Mix2190d
- Other10(48%)
- SEC Filings6(29%)
- Insider2(10%)
- Earnings2(10%)
- Leadership1(5%)
Latest news
25 items- PRAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on May 29, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.02 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the shar
- PRAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY. A live webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com. A replay of the webcast will also be available for 90 days following the presentation. The 2026 Jefferies Global Healthcare Confe
- SECSEC Form SCHEDULE 13G filed by Akebia Therapeutics Inc.SCHEDULE 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)
- SECSEC Form 10-Q filed by Akebia Therapeutics Inc.10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)
- SECAkebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
- PRAkebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline HighlightsQ1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better t
- PRAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 208,800 shares of Akebia's common stock on April 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.38 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the s
- PRAkebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of NephrologyCAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the Journal of the American Society of Nephrology (JASN), a leading, high-impact, peer-reviewed journal in nephrology. "The win statistics analysis highlighted favorable outcomes and potential clinical differentiation for Vafseo that we believe are central to ensure informed clinical decision-making for nephrologists and other care providers
- PRAkebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business HighlightsAkebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 7, 2026, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the
- SECSEC Form DEF 14A filed by Akebia Therapeutics Inc.DEF 14A - Akebia Therapeutics, Inc. (0001517022) (Filer)
- SECSEC Form DEFA14A filed by Akebia Therapeutics Inc.DEFA14A - Akebia Therapeutics, Inc. (0001517022) (Filer)
- SECSEC Form PRE 14A filed by Akebia Therapeutics Inc.PRE 14A - Akebia Therapeutics, Inc. (0001517022) (Filer)
- PRAkebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury (AKI). The Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose (SAD/MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKB-9090 administered intr
- PRAkebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation SymposiumCAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium. During meetings, management will discuss its commercial products, and data and other information shared during Akebia's recent R&D Day that sho
- INSIDERSEC Form 4 filed by Vickers Philip J.4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- INSIDERSEC Form 3 filed by new insider Vickers Philip J.3 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- PRAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 13 newly-hired employees options to purchase an aggregate of 679,900 shares of Akebia's common stock on March 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.39 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of th
- SECAkebia Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
- PRAkebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of DirectorsCAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of biopharmaceutical leader Philip J. Vickers to its Board of Directors, effective April 1, 2026. Dr. Vickers is the President and Chief Executive Officer and a member of the Board of Directors of Solu Therapeutics, a venture-backed biotechnology company focused on creating first-in-class therapeutics utilizing a novel drug discovery platform, and he has held senior leadership positions at several early-stage biotechnology companies as well as global pharmaceutica
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Akebia Therapeutics Inc.SCHEDULE 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
- PRAkebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT. To register for the Akebia virtual R&D Day, click here. The event will feature scientific experts James A. Tumlin, MD (NephroNet), V. Michael Holers, MD (University of Colorado Anschutz) and Jonathan Barratt, MD, PhD, FRCP (University of Leicester) who will join management to discuss Akebia's robust pipeline of clinical stage kidney diseases programs: Praliciguat, a soluble guanylate cyclase stimul
- INSIDERCEO and President Butler John P. bought $86,588 worth of shares (69,270 units at $1.25), increasing direct ownership by 2% to 3,367,064 units (SEC Form 4)4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- PRAkebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare ConferenceCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9 at 8:00 AM ET. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. The Leerink Partners 2026 Global Healthcare Conference will take place March 8-11, 2026, in Miam
- PRAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 46,200 shares of Akebia's common stock on February 27, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.31 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% o
- SECSEC Form 10-K filed by Akebia Therapeutics Inc.10-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
AKBA FAQ
7 questionsWhat does Akebia Therapeutics Inc. do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in...Where does AKBA stock trade?
Akebia Therapeutics Inc. (AKBA) is listed on NASDAQ.What sector and industry is AKBA in?
Akebia Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Akebia Therapeutics Inc. go public?
Akebia Therapeutics Inc. (AKBA) completed its IPO in 2014.What are analysts saying about AKBA?
Akebia Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $800.00 price target on 2025-06-04. Recent price targets range from $200.00 to $800.00.What companies are similar to AKBA?
Notable peers in the same industry include ISEE (IVERIC bio Inc.), ARDX (Ardelyx Inc.), FGEN (FibroGen Inc), KDNY (Chinook Therapeutics Inc.), TCDA (Tricida Inc.). Compare AKBA side-by-side with any of them on Quantisnow.How can I track AKBA on Quantisnow?
Quantisnow aggregates Akebia Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKBA to receive live email and push alerts on every new disclosure.